Phase II trial of concurrent sunitinib and image-guided radiotherapy for oligometastases.
PLoS ONE., 7(6):e36979 (2012)
Update on prostate brachytherapy: long-term outcomes and treatment-related morbidity.
Curr Urol Rep., Jun;12(3):237-42 (2011)
Young men have equivalent biochemical outcomes compared with older men after treatment with brachytherapy for prostate cancer.
Int. J. Radiat. Oncol. Biol. Phys., Aug;77(5):1315-21 (2010)
Does neoadjuvant hormonal therapy improve urinary function when given to men with large prostates undergoing prostate brachytherapy?
J. Urol., Feb;183(2):634-9 (2010)
Do high radiation doses in locally advanced prostate cancer patients treated with 103Pd implant plus external beam irradiation cause increased urinary, rectal, and sexual morbidity?
Brachytherapy., 9(2):114-8 (2010 Apr-Jun)
Local control following permanent prostate brachytherapy: effect of high biologically effective dose on biopsy results and oncologic outcomes.
Int. J. Radiat. Oncol. Biol. Phys., Feb;76(2):355-60 (2010)
Phase 1 study of concurrent sunitinib and image-guided radiotherapy followed by maintenance sunitinib for patients with oligometastases: acute toxicity and preliminary response.
Cancer., Aug;115(15):3571-80 (2009)
Outcomes for patients with high-grade prostate cancer treated with a combination of brachytherapy, external beam radiotherapy and hormonal therapy.
BJU Int., Dec;104(11):1631-6 (2009)
Radiation dose predicts for biochemical control in intermediate-risk prostate cancer patients treated with low-dose-rate brachytherapy.
Int. J. Radiat. Oncol. Biol. Phys., Sep;75(1):16-22 (2009)
Prognostic significance of 5-year PSA value for predicting prostate cancer recurrence after brachytherapy alone and combined with hormonal therapy and/or external beam radiotherapy.
Int. J. Radiat. Oncol. Biol. Phys., Jul;74(3):753-8 (2009)
There is no correlation between erectile dysfunction and dose to penile bulb and neurovascular bundles following real-time low-dose-rate prostate brachytherapy.
Int. J. Radiat. Oncol. Biol. Phys., Apr;73(5):1468-74 (2009)
Distant and local recurrence in patients with biochemical failure after prostate brachytherapy.
Brachytherapy., 7(3):217-22 (2008 Jul-Sep)
Association of single nucleotide polymorphisms in SOD2, XRCC1 and XRCC3 with susceptibility for the development of adverse effects resulting from radiotherapy for prostate cancer.
Radiat. Res., Jul;170(1):49-59 (2008)
Stereotactic radiosurgery for thoracic malignancies.
Ann. Thorac. Surg., Feb;85(2):S785-91 (2008)
Adjuvant radiotherapy improves overall survival for patients with lymph node-positive head and neck squamous cell carcinoma.
Cancer., Feb;112(3):535-43 (2008)
(125)I monotherapy using D90 implant doses of 180 Gy or greater.
Int. J. Radiat. Oncol. Biol. Phys., Jan;70(1):96-101 (2008)
Brachytherapy for the treatment of prostate cancer.
Cancer J., 13(5):302-12 (2007 Sep-Oct)
TGFB1 single nucleotide polymorphisms are associated with adverse quality of life in prostate cancer patients treated with radiotherapy.
Int. J. Radiat. Oncol. Biol. Phys., Mar;70(3):752-9 (2008)
Effect of low dose-rate prostate brachytherapy on the sexual health of men with optimal sexual function before treatment: analysis at > or = 7 years of follow-up.
BJU Int., Aug;100(2):362-7 (2007)
Possession of ATM sequence variants as predictor for late normal tissue responses in breast cancer patients treated with radiotherapy.
Int. J. Radiat. Oncol. Biol. Phys., Nov;69(3):677-84 (2007)
A genetically determined dose-volume histogram predicts for rectal bleeding among patients treated with prostate brachytherapy.
Int. J. Radiat. Oncol. Biol. Phys., Aug;68(5):1410-6 (2007)
Is seminal vesicle implantation with permanent sources possible? A dose-volume histogram analysis in patients undergoing combined 103Pd implantation and external beam radiation for T3c prostate cancer.
Brachytherapy., 6(1):38-43 (2007 Jan-Mar)
Assessment of postbrachytherapy sexual function: a comparison of the IIEF-5 and the MSEFS.
Brachytherapy., 6(1):26-33 (2007 Jan-Mar)
Changing the patterns of failure for high-risk prostate cancer patients by optimizing local control.
Int. J. Radiat. Oncol. Biol. Phys., Oct;66(2):389-94 (2006)
Low-dose rate prostate brachytherapy is well tolerated in patients with a history of inflammatory bowel disease.
Int. J. Radiat. Oncol. Biol. Phys., Oct;66(2):424-9 (2006)
Genetic predictors of adverse radiotherapy effects: the Gene-PARE project.
Int. J. Radiat. Oncol. Biol. Phys., Jul;65(3):646-55 (2006)
Adjuvant radiation with modern techniques is the standard of care for stage III thymoma.
Ann. Thorac. Surg., Mar;81(3):1180-1; author reply 1181-2 (2006)
ATM sequence variants and risk of radiation-induced subcutaneous fibrosis after postmastectomy radiotherapy.
Int. J. Radiat. Oncol. Biol. Phys., Mar;64(3):776-83 (2006)
Disease-specific survival following the brachytherapy management of prostate cancer.
Int. J. Radiat. Oncol. Biol. Phys., Mar;64(3):810-6 (2006)
Biologically effective dose values for prostate brachytherapy: effects on PSA failure and posttreatment biopsy results.
Int. J. Radiat. Oncol. Biol. Phys., Feb;64(2):527-33 (2006)
ATM sequence variants are predictive of adverse radiotherapy response among patients treated for prostate cancer.
Int. J. Radiat. Oncol. Biol. Phys., Jan;61(1):196-202 (2005)
Does prior transurethral resection of prostate compromise brachytherapy quality: a dosimetric analysis.
Int. J. Radiat. Oncol. Biol. Phys., Oct;60(2):648-53 (2004)
Combined modality treatment in the management of high-risk prostate cancer.
Int. J. Radiat. Oncol. Biol. Phys., Aug;59(5):1352-9 (2004)
Urinary symptom flare following I-125 prostate brachytherapy.
Int. J. Radiat. Oncol. Biol. Phys., Jul;56(4):1085-92 (2003)
Prostate-specific antigen bounce after prostate seed implantation for localized prostate cancer: descriptions and implications.
Int. J. Radiat. Oncol. Biol. Phys., Jun;56(2):448-53 (2003)